Success Metrics

Completion Rate
0%(0/1)
Active Trials
0(0%)
Terminated
1(50%)

Phase Distribution

Ph phase_3
2
100%

Phase Distribution

0

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution2 total trials
Phase 3Large-scale testing
2(100.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Active(1)
Terminated(1)

Detailed Status

Enrolling by invitation1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Phase 32 (100.0%)

Trials by Status

enrolling_by_invitation150%
terminated150%

Recent Activity

0 active trials
Showing 2 of 2
enrolling_by_invitationphase_3

Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia

NCT04952610
terminatedphase_3

Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302

NCT03635996

Clinical Trials (2)

Showing 2 of 2 trials
NCT04952610Phase 3

Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia

Enrolling By Invitation
NCT03635996Phase 3

Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302

Terminated

All 2 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
2